Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$684M |
| 2 |
Amgen
AMGN
|
+$653M |
| 3 |
Salesforce
CRM
|
+$488M |
| 4 |
Eli Lilly
LLY
|
+$452M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$437M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$815M |
| 2 |
NVIDIA
NVDA
|
+$685M |
| 3 |
TJX Companies
TJX
|
+$488M |
| 4 |
Starbucks
SBUX
|
+$373M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$361M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.92% |
| 2 | Healthcare | 18.9% |
| 3 | Consumer Discretionary | 9.38% |
| 4 | Financials | 9.11% |
| 5 | Industrials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Carlisle Companies
CSL
$13.8B
| $136M | 0.07% |
334,410
-89,977
| -21% | -$36.3M |
|
227
EnerSys
ENS
$6.94B
| $135M | 0.07% |
1,307,582
+1,077
| +0.1% | +$106K |
|
228
Neurocrine Biosciences
NBIX
$17.7B
| $134M | 0.07% |
971,203
-407,310
| -30% | -$55.9M |
|
229
Structure Therapeutics
GPCR
$3.46B
| $132M | 0.07% |
3,354,269
+1,277,569
| +62% | +$52.5M |
|
|
FOLD
230
DELISTED
Amicus Therapeutics
FOLD
| $131M | 0.07% |
13,231,394
-583,120
| -4% | -$5.99M |
|
231
United Therapeutics
UTHR
$26.3B
| $131M | 0.07% |
410,010
-225,337
| -35% | -$59.6M |
|
232
Moody's
MCO
$84.2B
| $130M | 0.07% |
308,246
+278,886
| +950% | +$111M |
|
233
EOG Resources
EOG
$74.7B
| $128M | 0.07% |
1,018,357
-26,748
| -3% | -$3.43M |
|
|
NVO
234
Novo Nordisk
NVO
$220B
| $128M | 0.07% |
893,597
-424,113
| -32% | -$56.2M |
|
235
Keysight
KEYS
$53.6B
| $125M | 0.07% |
916,376
-264,460
| -22% | -$38.6M |
|
236
STAG Industrial
STAG
$7.77B
| $125M | 0.07% |
3,463,614
-528,892
| -13% | -$18.8M |
|
237
Arista Networks
ANET
$215B
| $124M | 0.07% |
1,416,852
-3,808
| -0.3% | -$283K |
|
238
AstraZeneca
AZN
$263B
| $124M | 0.07% |
792,026
-74,077
| -9% | -$11.1M |
|
239
S&P Global
SPGI
$130B
| $123M | 0.07% |
275,528
+16,802
| +6% | +$7.21M |
|
240
ITT
ITT
$17.7B
| $119M | 0.06% |
924,444
-102,318
| -10% | -$13.4M |
|
241
IBM
IBM
$204B
| $119M | 0.06% |
687,923
-29,279
| -4% | -$5.09M |
|
242
Welltower
WELL
$175B
| $119M | 0.06% |
1,136,439
-273,005
| -19% | -$26.8M |
|
243
Ares Management
ARES
$28.8B
| $117M | 0.06% |
875,781
+41,166
| +5% | +$5.62M |
|
244
Constellium
CSTM
$4.02B
| $116M | 0.06% |
6,151,984
-4,171,380
| -40% | -$86.8M |
|
245
Western Alliance Bancorporation
WAL
$9.04B
| $114M | 0.06% |
1,821,421
+204,130
| +13% | +$12.3M |
|
246
Public Storage
PSA
$60.5B
| $114M | 0.06% |
397,222
+376,141
| +1,784% | +$104M |
|
247
Gilead Sciences
GILD
$162B
| $114M | 0.06% |
1,663,494
-50,249
| -3% | -$3.35M |
|
248
Zai Lab
ZLAB
$2.1B
| $113M | 0.06% |
6,527,567
+2,099,556
| +47% | +$36.9M |
|
249
Zurn Elkay Water Solutions
ZWS
$8.14B
| $113M | 0.06% |
3,827,269
-37,859
| -1% | -$1.19M |
|
250
Western Digital
WDC
$172B
| $111M | 0.06% |
1,933,219
+1,877,179
| +3,350% | +$104M |
|
Similar funds
Janus Henderson Group's Q2 2024 Portfolio in Review
As of Q2 2024, Janus Henderson Group held 2,619 positions worth $187B, up 1.9% from $183B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Janus Henderson Group's Q2 2024 filing shows 91 new, 630 increased, 1,758 reduced and 101 closed positions. Its largest new stake was UL Solutions: 2,328,210 shares worth $98.2M. The largest sale was Adobe, an estimated $815M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q2 2024 buy was UL Solutions: 2,328,210 shares worth $98.2M.
- Janus Henderson Group added most to Broadcom in Q2 2024, an estimated $684M increase.
- Janus Henderson Group's biggest Q2 2024 reduction was Adobe, cutting an estimated $815M.
- Janus Henderson Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $157M.
- Janus Henderson Group's ten largest holdings make up 32% of its $187B portfolio in Q2 2024.
- Janus Henderson Group opened 91 new positions and closed 101 in Q2 2024.
- Janus Henderson Group's portfolio value rose 1.9% quarter-over-quarter to $187B.
Based on Janus Henderson Group's 13F filing for Q2 2024, filed 14 Aug 2024.